SCHEMBL30210344

SCHEMBL30210344

CN[C@@H]1CN(C(=O)OCc2ccccc2)CC12CC2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
CYP2C19 P33261 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HTT P42858 1/20 0.45
RORC P51449 2/20 0.45
HTR2C P28335 1/20 0.44
KDM1A O60341 2/20 0.43
GRIN2B Q13224 3/20 0.42
ENPP2 Q13822 2/20 0.42
ATXN2 Q99700 2/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
MMP1 P03956 1/20 0.40
MMP3 P08254 1/20 0.40
MMP7 P09237 1/20 0.40
MMP9 P14780 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL34473906 0.88 SMN1; SMN2 (0.46) SMN1; SMN2NPC1RAB9ACYP2C19MEN1
SCHEMBL30210320 0.83 PDE4B (0.47) SMN1; SMN2NPC1RAB9ACYP2C19MEN1
SCHEMBL31634703 0.83 PDE4B (0.47) SMN1; SMN2NPC1RAB9ACYP2C19MEN1
SCHEMBL34474162 0.83 SMN1; SMN2 (0.48) SMN1; SMN2NPC1RAB9ACYP2C19MEN1
SCHEMBL20520922 0.83 SMN1; SMN2 (0.48) SMN1; SMN2NPC1RAB9ACYP2C19MEN1
SCHEMBL29944831 0.82 RORC (0.42) SMN1; SMN2NPC1RAB9ACYP2C19MEN1
SCHEMBL22605195 0.81 SMN1; SMN2 (0.52) SMN1; SMN2NPC1RAB9ACYP2C19MEN1
SCHEMBL31634674 0.81 SMN1; SMN2 (0.52) SMN1; SMN2NPC1RAB9ACYP2C19MEN1
SCHEMBL30948974 0.81 GRM5 (0.44) SMN1; SMN2NPC1RAB9ACYP2C19MEN1
SCHEMBL31634701 0.81 GRM5 (0.44) SMN1; SMN2NPC1RAB9ACYP2C19MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4139299-B1 KRAS G12D PROTEIN INHIBITORS TAIHO PHARMACEUTICAL CO LTD (JP) 2025-12-17 EP disclosed
US-20230174518-A1 KRAS G12D PROTEIN INHIBITORS TAIHO PHARMACEUTICAL CO., LTD. (JP) 2023-06-08 US disclosed
EP-4139299-A1 KRAS G12D PROTEIN INHIBITORS Taiho Pharmaceutical Co., Ltd. (JP) 2023-03-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174518-A1 KRAS G12D PROTEIN INHIBITORS KRAS, NRAS, HRAS SMN1; SMN2 3079/4885NPC1 2655/4885RAB9A 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.